# DESCRIPTION

## BACKGROUND OF THE INVENTION

- introduce avian influenza virus
- limitations of current prophylactic methods

## BRIEF SUMMARY OF THE INVENTION

- introduce siRNA compositions for treating avian influenza
- describe nonpathogenic E. coli bacterium delivery system
- outline advantages of siRNA approach

## DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

- motivate anti-influenza technology
- limitations of current vaccination strategies
- RNA interference (RNAi) as alternative antiviral
- limitations of RNAi delivery mechanisms
- introduce transkingdom RNAi (tkRNAi) delivery platform
- describe tkRNAi system components
- demonstrate in vitro proof of concept for tkRNAi anti-AIV vectors
- discuss importance of targeting conserved regions in NP and PA genes
- highlight need for avian tissue model and relevance to poultry
- discuss economic and public health importance of AIV prevention
- outline goals and advantages of tkRNAi anti-AIV technology

### Design of siRNAs and Use of Viral Specific siRNAs to Inhibit Avian Influenza in an Avian Tissue Model

- introduce avian influenza virus and need for new prophylactic strategies
- describe avian tissue transfection and AIV infection model
- detail materials and methods for cell cultures, viruses, siRNAs, transfection efficiency, and virus infection
- outline evaluation of infectious virus titer and statistical analysis
- present results of siRNA antiviral activity in chicken cells
- discuss significance of results and potential for RNAi-based antiviral strategy
- introduce need for better delivery mechanism for RNAi-based antiviral

### Inhibiting Avian Influenza Replication in a Chicken Cell Model Using a Unique RNAi Delivery Technology

- motivate RNAi approach to combat AIV
- describe tkRNAi system and its potential
- validate Î²(1) integrin receptors on LMH cells
- construct and generate tkRNAi shRNA vectors
- verify intracellular uptake of tkRNAi vectors
- determine optimal tkRNAi vector concentration
- evaluate protective efficacy of anti-AIV vectors
- analyze results and discuss implications
- describe cell invasion with tkRNAi shRNA vectors
- outline virus infection and evaluation of infectious virus titer
- perform statistical analysis of results
- verify intracellular uptake of tkRNAi vectors and demonstrate antiviral activity
- discuss results and potential applications

### Prophylactic Treatment of Chicken Populations with Anti-AIV Vectors

- introduce anti-AIV vectors for poultry
- describe experimental design and methods
- detail vector administration and virus challenge
- outline data and sample collection procedures
- describe detection of viral shedding by RT-qPCR
- summarize serology and statistical analysis
- present pilot studies for vector uptake, dose, and virus challenge
- detail proof of concept study and sentinel chicken experiment
- report results of RFP-vector localization in chicken respiratory tissues
- describe pilot 2 study design
- report pilot 2 results
- describe pilot 3 study design
- report pilot 3 results
- describe final POC study design
- report final POC study results
- present experimental design
- analyze shedding titers and proportions
- discuss vector protection model
- assess shedding duration and titer
- evaluate vaccine protection criteria
- discuss prevention of contact transmission
- consider mucosal immune response
- address potential caveats and limitations
- summarize results and future directions

## GLOSSARY OF CLAIM TERMS

- define administration
- define composition
- define therapeutically effective amount
- define treating AIV
- define treatment
- define subject in need of treatment
- define other terms

